Cogent Corp (COGT) Enterprise Value to EBITDA Ratio

Public company logo of cogentbio.com (COGT)

The GURU.Markets terminal provides an EV/EBITDA multiple chart for Cogent Biosciences (COGT), where the value is fixed at 0.00. This price action confirms the transparency of clinical trials alongside effective capital raising. The development of targeted therapies against genetic pathologies minimizes scientific risks. Within precision oncology, Cogent Biosciences maintains a reputable image while awaiting final confirmation of its medical hypotheses.

Cogent Biosciences Inc - COGT Company Value to EBITDA (period 11/23/2025 - 11/12/2026)

Comprehensive metric breakdowns and analytics for cogentbio.com (COGT)

- current price and projected stock value:
Stock Price Cogent Bio|COGT - Analyst Median Target
- market capitalization details:
Market Valuation Cogent Corp|COGT - Full Business Value
- business book valuation details:
Book Value per Share Cogent Biosciences|COGT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio cogentbio.com|COGT - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Cogent Biosciences|COGT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cogent Biosciences, Inc.|COGT - Company Aggregate Indebtedness|Debts to Book Capitalization Cogent Corp|COGT - Company Long-Term Loans and Borrowings|Company Short-Term Debts Cogent Biosciences|Quick Liquidity cogentbio.com
- financial results and valuation multiples details:
COGT - Final Profit|Expected Profit Cogent Biosciences|COGT - Price to Earnings Ratio|Forward P/E Multiple Cogent Biosciences|COGT - PEG Multiple|EV/EBITDA Multiple Cogent Corp|COGT - Operating profit before deduction of amortization|Earnings per share for the last twelve months Cogent Biosciences|COGT - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth cogentbio.com|COGT - Net earnings per share change in current year|Earnings growth forecast for next year Cogent Biosciences
Fundamental valuation:Cogent Bio COGT
Manufactured products of Cogent Biosciences, Inc.

For Cogent Biosciences (COGT), which lacks pricing power until its drugs receive certification, this indicator is critical when assessing business value relative to operating profit. By analyzing the EV/EBITDA chart against historical data, an investor can see the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization, making it possible to identify asset overvaluation in the absence of market sales.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XERS (Xeris Pharma)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics)|ARCT (arcturusrx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Ltd) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (Abeona Therapeutics)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|Polyrizon Ltd (PLRZ) - Enterprise Value to EBITDA Ratio|zentaris.com (AEZS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|INZY (Inozyme Pharma Inc.) - EV/EBITDA Multiple|RPHM - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple CSCI